The Chamber of Commerce for Greater Philadelphia commissioned a study conducted by Econsult Solutions, Inc., titled The State of Cell and Gene Therapy in the Greater Philadelphia Region: A Comparative Analysis, which measured the impact of our region’s progress in cell and gene therapy through five key lenses: research infrastructure, human capital, innovation output, commercial activity, and value proposition. The study compared Greater Philadelphia to 14 other U.S. metros – Baltimore, Boston, Chicago, Cleveland, Houston, Indianapolis, Los Angeles, New York, Research Triangle, San Diego, San Francisco, Seattle, and Washington D.C. – and ranked Greater Philadelphia as the #2 cell and gene therapy hub.
Claire Greenwood, Executive Director and Senior Vice President of Economic Competitiveness, and Sarah Steltz, Vice President of Economic Competitiveness for the Chamber discussed what this means for the region in Cell & Gene. Read the full Cell & Gene article here.
Leave A Comment